Metagenomi Chief Scientific Officer Departs Just Months After IPO

Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for introducing drugs related to medical health, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.

The chief scientific officer of gene editing company Metagenomi has resigned, according to the company.Endpoints NewsConfirmed.

"As of yesterday, I have parted ways with Metagenomi through a mutual agreement," CSO Louis Borges posted on LinkedIn last week. He last yearJoin the company, previously holding the same position at cell therapy manufacturer Century Therapeutics.

His departure came as the Emeryville, California-based startup was in the process ofInitial Public OfferingJust five months later, amid the weak public markets of the past few years, forPreclinical BiotechnologyFor the company, which is a rare move. The company priced its IPO at $15 per share in February, and today it trades at around $5 per share.

"We have reached a mutual separation with Luis Borges and wish him all the best in his future endeavors," a Metagenomi spokesperson said via email.。

Source: https://endpts.com/